GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Shiller PE Ratio

ESSA Pharma (ESSA Pharma) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ESSA Pharma Shiller PE Ratio Historical Data

The historical data trend for ESSA Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Shiller PE Ratio Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ESSA Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ESSA Pharma's Shiller PE Ratio

For the Biotechnology subindustry, ESSA Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Shiller PE Ratio falls into.



ESSA Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ESSA Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, ESSA Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.2/126.2576*126.2576
=-0.200

Current CPI (Mar. 2024) = 126.2576.

ESSA Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.312 99.473 -1.665
201409 -0.598 99.394 -0.760
201412 -1.600 98.367 -2.054
201503 -4.000 99.789 -5.061
201506 -5.800 100.500 -7.286
201509 1.400 100.421 1.760
201512 -3.600 99.947 -4.548
201603 -0.800 101.054 -1.000
201606 -2.600 102.002 -3.218
201609 -3.000 101.765 -3.722
201612 1.000 101.449 1.245
201703 -5.230 102.634 -6.434
201706 2.320 103.029 2.843
201709 -1.400 103.345 -1.710
201712 -1.440 103.345 -1.759
201803 -0.830 105.004 -0.998
201806 -0.500 105.557 -0.598
201809 -0.390 105.636 -0.466
201812 -0.430 105.399 -0.515
201903 -0.540 106.979 -0.637
201906 -0.520 107.690 -0.610
201909 -0.070 107.611 -0.082
201912 -0.220 107.769 -0.258
202003 -0.450 107.927 -0.526
202006 -0.240 108.401 -0.280
202009 -0.170 108.164 -0.198
202012 -0.200 108.559 -0.233
202103 -0.360 110.298 -0.412
202106 -0.210 111.720 -0.237
202109 -0.200 112.905 -0.224
202112 -0.210 113.774 -0.233
202203 -0.250 117.646 -0.268
202206 -0.200 120.806 -0.209
202209 -0.140 120.648 -0.147
202212 -0.150 120.964 -0.157
202303 -0.160 122.702 -0.165
202306 -0.170 124.203 -0.173
202309 -0.120 125.230 -0.121
202312 -0.140 125.072 -0.141
202403 -0.200 126.258 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ESSA Pharma  (NAS:EPIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ESSA Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104